Trijardy XR is a once-daily tablet that combines three different type 2 diabetes medications — empagliflozin, linagliptin, and metformin extended-release — into one pill. FDA approved in January 2020, it remains the only fixed-dose three-drug oral combination for diabetes available in the United States, designed for patients who need or already take all three medications and want to simplify their regimen.
What Trijardy XR Contains
Trijardy XR is jointly marketed by Boehringer Ingelheim and Eli Lilly. Each tablet delivers three active ingredients with complementary mechanisms:
- Empagliflozin — an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, causing 70 to 80 grams of glucose to be excreted in urine daily. It also lowers blood pressure, reduces body weight, and provides cardiovascular and kidney protection.
- Linagliptin — a DPP-4 inhibitor that prolongs the activity of GLP-1 and GIP, hormones that stimulate insulin release after meals and suppress glucagon. Weight neutral and well tolerated. Unique among DPP-4 inhibitors in requiring no dose adjustment for kidney impairment.
- Metformin hydrochloride extended-release — reduces hepatic glucose output and improves insulin sensitivity. The extended-release formulation reduces gastrointestinal side effects compared with immediate-release metformin.
The three drugs hit three different physiological levers — the kidney, the gut-pancreas axis, and the liver — which is why their combined effect is additive and meaningful even when each is at a moderate dose.
Available Strengths
| Strength | Empagliflozin | Linagliptin | Metformin XR |
|---|---|---|---|
| 5/2.5/1000 | 5 mg | 2.5 mg | 1,000 mg |
| 10/5/1000 | 10 mg (2 of 5 mg) | 5 mg (2 of 2.5 mg) | 1,000 mg (1 of 1000 mg) |
| 12.5/2.5/1000 | 12.5 mg | 2.5 mg | 1,000 mg |
| 25/5/1000 | 25 mg | 5 mg | 1,000 mg |
Maximum daily dose is empagliflozin 25 mg, linagliptin 5 mg, and metformin XR 2,000 mg, achieved with two of the 12.5/2.5/1000 tablets or one 25/5/1000 plus one 1,000 mg metformin tablet (or other combinations as a clinician directs).
Dosing Instructions
- Take once daily with the morning meal to minimize gastrointestinal side effects.
- Swallow whole — do not crush, split, or chew (the metformin extended-release matrix must stay intact).
- If a dose is missed and it is still the same day, take it as soon as remembered with food. Skip if it is nearly time for the next dose.
- Drink adequate water throughout the day to support kidney function and reduce dehydration from the SGLT2 component.
Who Trijardy XR Is For
Trijardy XR is indicated for adults with type 2 diabetes when diet, exercise, and other medications have not achieved adequate glycemic control. It is most appropriate when:
- A1C remains above goal on dual therapy (typically metformin plus one other drug)
- All three classes are already prescribed and the patient wants to reduce pill burden
- Cardiovascular disease, heart failure, or chronic kidney disease makes empagliflozin’s outcome benefits desirable
- Weight gain from other diabetes medications has been a concern (linagliptin is weight neutral, empagliflozin causes mild weight loss)
It is not approved for type 1 diabetes, diabetic ketoacidosis, or use in children.
How Well It Works
Pooled data from registration trials and the individual component evidence show:
- A1C reduction: approximately 2.0 to 2.5 percent in patients with baseline A1C above 9.0 percent. Smaller absolute reductions in those already closer to goal.
- Weight change: 2 to 4 kg loss over 24 to 52 weeks, driven by empagliflozin.
- Blood pressure: systolic reduction of 3 to 5 mmHg.
- Cardiovascular events: the EMPA-REG OUTCOME trial of empagliflozin showed a 14 percent relative risk reduction in major adverse cardiovascular events and 38 percent reduction in cardiovascular death in patients with established CVD.
- Kidney protection: the EMPA-KIDNEY trial demonstrated a 28 percent reduction in progression to kidney failure or cardiovascular death.
If you are still in the prediabetes phase, see our discussion of A1C levels for context on what a 2 percent reduction means clinically.
Side Effects
| Side Effect | From Which Component | Approximate Frequency |
|---|---|---|
| Genital yeast infections | Empagliflozin | 4 to 12 percent |
| Urinary tract infections | Empagliflozin | 7 to 9 percent |
| Diarrhea, nausea, gas | Metformin XR | 5 to 15 percent (improves over weeks) |
| Upper respiratory tract infection | Linagliptin | 6 to 7 percent |
| Nasopharyngitis, sore throat | Linagliptin | 6 percent |
| Headache | All three | 5 percent |
| Increased urination, thirst | Empagliflozin | 3 to 5 percent |
| Hypoglycemia (when combined with insulin/sulfonylurea) | All three | Varies |
| Pancreatitis | Linagliptin | Rare (less than 0.5 percent) |
| Severe joint pain | Linagliptin (class effect) | Rare |
| Euglycemic DKA | Empagliflozin | Rare (less than 0.1 percent) |
| Lactic acidosis | Metformin | Very rare |
Contraindications and Warnings
- eGFR less than 30 mL/min/1.73 m squared: contraindicated (metformin).
- eGFR 30 to 45: avoid initiation; existing users may continue with caution and dose adjustment.
- History of serious hypersensitivity to any component.
- Active diabetic ketoacidosis.
- Severe hepatic impairment.
- Acute or chronic metabolic acidosis.
- Hold around iodinated contrast imaging and major surgery.
- Use caution in heart failure — although empagliflozin is beneficial, fluid changes warrant monitoring.
- Prior pancreatitis — caution due to the DPP-4 component.
Drug Interactions
- Strong CYP3A4 and P-gp inducers (rifampin, carbamazepine, phenytoin, St. John’s wort): may reduce linagliptin levels.
- Diuretics: additive volume depletion.
- Insulin and sulfonylureas: increase hypoglycemia risk; doses may need reduction.
- Cationic drugs (cimetidine, dolutegravir): increase metformin exposure.
- Alcohol: increases lactic acidosis risk.
- Iodinated contrast: hold Trijardy XR 48 hours before and after.
Cost and Coverage
Without insurance, Trijardy XR retails for approximately $600 to $750 per month. Boehringer Ingelheim and Lilly offer a savings card for commercially insured patients, often reducing the out-of-pocket cost to $10 to $50 per month for up to 24 months. Medicare and Medicaid recipients are not eligible for the savings card but may qualify for patient assistance based on income. Many commercial formularies place Trijardy XR on Tier 3 or specialty tiers with higher copays — confirm coverage with your plan before starting.
Storage
- Store at controlled room temperature 68 to 77 degrees F (20 to 25 degrees C).
- Keep in the original blister or bottle.
- Protect from moisture.
- Do not use after the expiration date printed on the package.
Comparison: Trijardy XR vs Separate Components
| Approach | Pill Burden | Approx Monthly Cost (no insurance) | Convenience |
|---|---|---|---|
| Trijardy XR (1 pill once daily) | 1 pill/day | $600 to $750 | Highest |
| Jardiance + Tradjenta + metformin XR (separate) | 3 pills/day | $1,100 to $1,400 | Lower (3 bottles) |
| Synjardy + linagliptin separately | 3 pills/day (BID + once) | $1,000 to $1,200 | Intermediate |
| Glyxambi + metformin separately | 2 pills/day | $900 to $1,100 | Intermediate |
Combining three brand drugs into one pill provides clear adherence and cost advantages over the separate-component approach, since the manufacturer prices the combination similarly to a single brand drug.
Place in Modern Type 2 Diabetes Care
The ADA Standards of Care recommend a stepwise approach: lifestyle plus metformin, then add a second agent based on cardiovascular or kidney comorbidities, then a third if A1C remains uncontrolled. Trijardy XR meets the third step for patients whose clinicians prefer all three component classes. Compared with adding a GLP-1 agonist injection at the third step, Trijardy XR avoids needles and the gastrointestinal burden of GLP-1 agents, though GLP-1 agonists generally produce greater weight loss and A1C reduction. Review our broader piece on diabetes treatment options for context on where Trijardy XR fits.
What to Tell Your Doctor Before Starting
- Current kidney function (eGFR)
- History of pancreatitis, gallbladder disease, or recurrent UTIs
- Heart failure status and recent decompensations
- Alcohol consumption patterns
- Other medications, including over-the-counter and supplements
- Pregnancy plans (Trijardy XR is not recommended in second or third trimester)
- Recent or upcoming surgery or contrast imaging
Practical Tips for Starting Trijardy XR
- Begin with the lowest strength that matches or slightly exceeds your prior component doses, then titrate if A1C remains above goal after 8 to 12 weeks.
- Pair the dose consistently with the morning meal — adherence is highest when the pill is part of a routine.
- Drink an extra 8 to 16 ounces of water daily to support kidney function and reduce dehydration risk.
- Practice good genital hygiene to reduce yeast infection risk; uncircumcised men should rinse the foreskin daily.
- Stop and call your clinician immediately if you develop severe abdominal pain, persistent vomiting, fruity breath, or rapid breathing — these can signal pancreatitis or DKA.
The Bottom Line
Trijardy XR is the only fixed three-drug oral combination for type 2 diabetes, packaging empagliflozin, linagliptin, and metformin extended-release into one once-daily tablet. Combined A1C reduction reaches 2.0 to 2.5 percent, with added benefits of weight loss, blood pressure improvement, cardiovascular protection, and kidney protection — particularly important for patients with established cardiovascular or kidney disease. Common side effects include genital infections, mild gastrointestinal symptoms, and upper respiratory infections; rare but serious risks include pancreatitis, euglycemic DKA, and lactic acidosis. It is most useful for patients already on or needing all three classes who want to simplify a three-pill regimen. Cost is similar to a single brand drug rather than three separately, making the combination economically attractive for many commercially insured patients. Talk to your clinician about whether consolidating to Trijardy XR makes sense for your regimen, kidney function, and budget.
